| Day 1 – Thursday, September 18, 2025 | |
|---|---|
| 14:00-15:45 | Session 1: Introduction to CAR-T- and T-cell engagers in autoimmunity |
| 14:00-14:15 | Welcome Dror Mevorach, Israel, Mohamad Mohty, France, Arnon Nagler, Israel |
| 14:15-15:00 | Plenary lecture: SLE pathogenesis and CAR T regulatory cell treatment George Tsokos, USA |
| 15:00-15:45 | From SLE to myasthenia gravis: What are the current bispecific/tri-specific T-cell engagers and CAR T in development for autoimmunity? Dror Mevorach, Israel |
| 16:00-16:30 | Coffee break |
| 16:30-17:15 | Session 2: Resetting autoimmunity treatment |
| 16:30-17:00 | Rheumatoid arthritis: From inverse pyramid through biologics to CAR T and BiTE. Historical perspective Josef Smolen, Austria |
| 17:00-17:30 | Resetting autoimmunity in immune-mediated inflammatory diseases Gerhard Krönke, Germany |
| 17:30-18:15 | Session 3: Oral Abstract Presentations |
| 18:45 | WELCOME RECEPTION |
| Day 2 – Friday, September 19, 2025 | |
|---|---|
| 09:00-10:30 | Session 4: From haemato-oncology to rheumatology |
| 09:00-09:30 | CAR T-cells: From hematology to autoimmunity Arnon Nagler, Israel |
| 09:30-10:00 | Current European guidelines for HSCT and CAR T in autoimmune diseases Raffaella Greco, Italy |
| 10:00-10:30 | CAR-T- and T-cell engagers Fabian Müller, Germany |
| 10:30-11:00 | Coffee break |
| 11:00-13:00 | Session 5: |
| 11:00-11:30 | TBA |
| 11:30-12:00 | CAR T for scleroderma? Could we cure the disease? TBA |
| 12:00-12:30 | CAR T in neurological autoimmunity Aiden Haghikia, Germany |
| 12:30-13:00 | Targeting BCMA for autoimmunity Chamutal Gur, Israel |
| 13:00-14:00 | Lunch |
| 14:00-16:00 | Session 6: Miscellaneous cell therapies for autoimmunity |
|
14:00-14:45 |
Plenary lecture: CRISPR-based T-cell editing for allogenic CAR T Huji Xu, China |
|
14:45-15:15 |
Are cells from patients with autoimmunity suitable for CAR T generation? Limits and perspectives |
|
15:15-15:45 |
NK cell therapy: from oncology to autoimmunity TBA |
|
15:45-16:15 |
Additional cell therapies and their role in autoimmunity (iPSCs, MSC, apoptotic) TBA |
|
16:15-16:45 |
Coffee break |
|
16:45-18:15 |
Session 7: |
|
16:45-17:15 |
Oral presentations |
|
17:15-18:15 |
Poster viewing |
|
18:15-19:00 |
Session 8: |
|
18:15-19:00 |
Debate: Autologous or heterologous CAR T therapy for autoimmunity? TBA |
| 19:30 | FACULTY DINNER |
| Day 3 – Saturday, September 20, 2025 | |
|---|---|
| 09:00-10:30 | Session 9: |
| 09:00-09:30 | T-cell engagers in autoimmune diseases Ricardo Grieshaber-Bouyer, Germany |
| 09:30-10:00 | CAR T safety in autoimmune diseases Melanie Hagen, Germany |
| 10:00-10:30 | Is there a cancer risk in treating patients with CAR T? Remy Dulery, USA |
| 10:30-11:00 | Coffee break |
| 11:00-13:00 | Session 10: |
| 11:00-11:30 | TBA |
| 11:30-12:00 | Commercially conscious development of cell therapies TBA |
| 12:00-12:30 | CAR T for ANCA vasculitis Avery Posey, Jr., USA |
| 12:30-13:00 | TBA |
| 13:00-14:00 | Lunch |
| 14:00-16:00 | Session 11: Near future perspectives |
| 14:00-14:30 | CAR T-IL-10 Tang Li, Switzerland |
| 14:30-15:00 | Increasing CAR T efficiency Jamie Frankish, Ireland |
| 15:00-15:30 | Systematic identification of targets improving Tcell therapies Laurie Menger, France |
| 16:00-16:30 | Coffee break |
| 16:30-18:00 | Session 12: |
| 16:30-17:30 | Debate: CAR T or BiTE for autoimmunity? TBA |
| 17:30 | Closing remarks Dror Mevorach, Israel, Mohamad Mohty, France, Arnon Nagler, Israel |
